Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation.
Arnold LeeHannah A BlairPublished in: Drugs (2021)
Dextenza®, an intracanalicular insert that is placed into the lower punctal opening of the eye, gradually releases dexamethasone for up to 30 days to alleviate pain and inflammation associated with ophthalmic surgery. A significantly higher proportion of patients treated with the dexamethasone intracanalicular insert than with the placebo insert had no pain at day 8 (co-primary endpoint, 7 days post-operation) across three pivotal phase III trials, and the inflammation co-primary endpoint (absence of anterior chamber cells) at day 14 (13 days post-operation) was met in two of three trials. Overall, the dexamethasone intracanalicular insert was effective and generally well tolerated for the treatment of post-surgical ocular pain and inflammation following cataract surgery. As low patient adherence is an issue for topical ophthalmic anti-inflammatory medications, the convenience (ease of insertion, single application with no patient input and typically no removal required) of the dexamethasone intracanalicular insert makes it a promising emerging option for the treatment of ocular inflammation and pain following ophthalmic surgery.
Keyphrases
- chronic pain
- oxidative stress
- pain management
- neuropathic pain
- low dose
- high dose
- phase iii
- minimally invasive
- induced apoptosis
- type diabetes
- randomized controlled trial
- case report
- coronary artery bypass
- metabolic syndrome
- cataract surgery
- insulin resistance
- anti inflammatory
- double blind
- cell death
- spinal cord injury
- cell proliferation
- percutaneous coronary intervention